Moleculin Historical Income Statement

MBRX
 Stock
  

USD 1.47  0.02  1.38%   

Historical analysis of Moleculin Biotech income statement accounts such as Selling General and Administrative Expense of 6.9 M can show how well Moleculin Biotech CS performed in making a profits. Evaluating Moleculin Biotech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Moleculin Biotech's future profits or losses. Financial Statement Analysis is much more than just reviewing and examining Moleculin Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Moleculin Biotech is a good buy for the upcoming year.
Additionally, see Stocks Correlation.
  
Refresh

Moleculin Biotech Net Income

(16.31 Million)

Share

About Moleculin Income Statement Analysis

Moleculin Biotech Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Moleculin Biotech shareholders. The income statement also shows Moleculin investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Moleculin Biotech Income Statement Chart

Moleculin Biotech CS Income Statement is one of the three primary financial statements used for reporting Moleculin's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Moleculin Biotech revenue and expense. Moleculin Biotech Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Moleculin Biotech Interest Expense is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Interest Expense of 38,700 in 2021. Weighted Average Shares is likely to rise to about 29 M in 2022, whereas Consolidated Income is likely to drop (16.3 M) in 2022.

Earning Before Interest and Taxes EBIT

Earnings Before Interest and Tax is calculated by adding Income Tax Expense and Interest Expense back to Net Income.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Moleculin Biotech financial statement analysis. It represents the amount of money remaining after all of Moleculin Biotech CS operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends.

Operating Income

Operating Income is the amount of profit realized from Moleculin Biotech operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Moleculin Biotech CS is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Operating income is a measure of financial performance before the deduction of Interest Expense; Income Tax Expense and other Non-Operating items. It is calculated as [GP] minus Operating Expenses.
Most accounts from Moleculin Biotech income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Moleculin Biotech current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Additionally, see Stocks Correlation.Moleculin Biotech Interest Expense is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Interest Expense of 38,700 in 2021. Weighted Average Shares is likely to rise to about 29 M in 2022, whereas Consolidated Income is likely to drop (16.3 M) in 2022.

Moleculin Biotech income statement Correlations

Moleculin Biotech Account Relationship Matchups

Moleculin Biotech income statement Accounts

201720182019202020212022 (projected)
Consolidated Income(9.8 M)(11.88 M)(13.21 M)(17.36 M)(15.89 M)(16.31 M)
Earning Before Interest and Taxes EBIT(9.8 M)(11.88 M)(13.43 M)(17.36 M)(15.89 M)(16.31 M)
Earning Before Interest and Taxes USD(9.8 M)(11.88 M)(13.43 M)(17.36 M)(15.89 M)(16.31 M)
Net Income(9.8 M)(11.88 M)(13.21 M)(17.36 M)(15.89 M)(16.31 M)
Net Income Common Stock(9.8 M)(11.88 M)(13.21 M)(17.36 M)(15.89 M)(16.31 M)
Net Income Common Stock USD(9.8 M)(11.88 M)(13.21 M)(17.36 M)(15.89 M)(16.31 M)
Operating Expenses8.65 M15.03 M17.52 M19.74 M22.97 M18.6 M
Operating Income(8.65 M)(15.03 M)(17.52 M)(19.74 M)(22.97 M)(23.57 M)
Research and Development Expense4.54 M9.73 M11.01 M12.76 M14.42 M11.56 M
Selling General and Administrative Expense4.09 M5.23 M6.31 M6.79 M8.39 M6.9 M
Weighted Average Shares3.09 M4.32 M6.79 M9.85 M26.88 M29 M
Weighted Average Shares Diluted3.09 M4.32 M6.79 M9.85 M26.88 M29 M

Moleculin Biotech Investors Sentiment

The influence of Moleculin Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Moleculin. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moleculin Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moleculin Biotech's short interest history, or implied volatility extrapolated from Moleculin Biotech options trading.

Current Sentiment - MBRX

Moleculin Biotech Investor Sentiment

Most of Macroaxis users are now bullish on Moleculin Biotech CS. What is your trading attitude regarding investing in Moleculin Biotech CS? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fund Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
41.2 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.